Crown Laboratories Announces Completion of Acquisition of Revance Therapeutics
The business combination reinforces Crown's position as a leading, innovative, high-growth aesthetics and skincare company
JOHNSON CITY, Tenn., Feb. 6, 2025 /PRNewswire/ -- Crown Laboratories, Inc. ("Crown"), a privately held, global innovative leader in the skincare industry, today announced the successful closing of its acquisition of Revance Therapeutics, Inc. ("Revance") (NASDAQ:RVNC), a biotechnology company aimed at setting the new standard in healthcare with innovative aesthetic and therapeutic offerings.
The Offer and the Merger
Crown's tender offer to acquire all of
